Medpace Holdings (FRA:01P) Ending Cash Position: €436 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:01P Medpace Holdings Inc FRA:01P
97 GF Score
Price €498.30
GF Value €459.14
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings Ending Cash Position?

Medpace Holdings FRA:01P -1.09% 97 Ending Cash Position is €436 Mil as of Jun. 2026. GuruFocus rates FRA:01P with a GF Score™ of 97/100 and a GF Value™ of €459.14 (Fairly Valued). The stock has 2 warning signs investors should review.

Medpace Holdings's Ending Cash Position for the quarter that ended in Jun. 2026 was €436 Mil.

Medpace Holdings's quarterly Ending Cash Position increased from Dec. 2025 (€424 Mil) to Mar. 2026 (€565 Mil) but then declined from Mar. 2026 (€565 Mil) to Jun. 2026 (€436 Mil).

Medpace Holdings's annual Ending Cash Position increased from Dec. 2023 (€225 Mil) to Dec. 2024 (€639 Mil) but then declined from Dec. 2024 (€639 Mil) to Dec. 2025 (€424 Mil).

Medpace Holdings Ending Cash Position Related Terms

Medpace Holdings Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Medpace Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medpace Holdings Ending Cash Position Chart

Medpace Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 408.25 26.68 225.08 639.31 424.48

Medpace Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.17 243.12 424.48 564.57 436.33
FRA:01P
97GF Score
Medpace Holdings Inc FRA:01P
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medpace Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Medpace Holdings's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=571.699+-147.219
=424

Medpace Holdings's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=566.526+-130.193
=436

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €436 Mil mean?
Medpace Holdings (FRA:01P) has a Ending Cash Position of €436 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Medpace Holdings and its competitors.
Is Medpace Holdings' Ending Cash Position too high?
Medpace Holdings' current Ending Cash Position is €436 Mil. Overall, Medpace Holdings has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Ending Cash Position compare to GH and ICLR?
Medpace Holdings' Ending Cash Position of €436 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current Ending Cash Position is €436 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (FRA:01P) is currently considered Fairly Valued. The stock's GF Value™ is €459.14, compared to a current price of €498.30 — trading 8.5% above its estimated fair value. The current Ending Cash Position is €436 Mil. Medpace Holdings' overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Medpace Holdings (FRA:01P), the current Ending Cash Position is €436 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medpace Holdings (FRA:01P) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of €498.30 is trading 8.5% above its estimated GF Value™ of €459.14. GuruFocus considers Medpace Holdings to be Fairly Valued.

Key valuation signals for FRA:01P:

  • Ending Cash Position: €436 Mil
  • GF Value™: €459.14 vs. price of €498.30 (8.5% above fair value)
  • GF Score™: 97/100 with 2 warning signs

No single metric tells the full story. See the FRA:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medpace Holdings Business Description

Other Exchanges MEDP:USAMEDP:Mexico
Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
97GF Score

Get the complete analysis for FRA:01P

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€498.30
Price
€459.14
GF Value